Smallpox was one of the most terrifying diseases in human history. Smallpox plagued humanity for thousands of years, killing one-third of its victims and disfiguring those who survived.

Phase 1 Clinical Trial of Sm-TSP-2 Schistosomiasis Vaccine Begins

WASHINGTON, D.C. — June 3, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today released an update on a Phase 1 clinical trial of its vaccine candidate to prevent intestinal schistosomiasis, Sm-TSP-2/Alhydrogel®. Schistosomiasis is one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poorest communities. The Sabin PDP is based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine (BCM) in Houston, Texas.


Subscribe to RSS - Sabin Vaccine Development